Earlier this year, the FDA approved 2 new indications for Aquaflor. According to Merck, the supplemental approval increased ...

Various veterinary businesses and organizations recently announced new promotions and appointments. The following individuals ...

While it costs money to own a pet under all circumstances, some unexpected expenses can catch owners unawares and put them in ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Merck’s Animal health and vaccine products are core growth drivers. It has a strong cancer pipeline, including Keytruda. Merck is investing in M&A activity to strengthen its pipeline.

Merck & Co., Inc.'s Q3 earnings report is anticipated on 31st October — next Thursday. Despite strong Q2 performance, Merck's stock fell due to a guidance downgrade related to issues with key ...

Merck & Co. is putting down $30 million upfront to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma (GBM).

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.